OSSIO Closes Series C Financing of $38.5 Million
Summary
Along with the participation of current shareholders, the round was led by MVM Partners, a Boston- and London-based growth equity firm investing in innovative, commercial stage healthcare companies that address high unmet medical needs.We are delighted to have secured this level of interest and commitment from such an experienced and distinguished medical technology investment firm, said OSSIOs chief executive officer, Brian Verrier. The additional funding will enable us to accelerate further adoption of OSSIOfiber\xae Intelligent Bone Regeneration Technology by orthopedic and podiatric surgeons in the United States. OSSIOfiber is engineered to provide the strength required for functional fixation and allows for full integration into the native anatomy without adverse biological response. Founded in 2014, its vision is to provide the first credible replacement to metal implants in the multibillion-dollar global orthopedic fixation market with its OSSIOfiber Intelligent Bone Regeneration Technology. For more information on the company, visit www.ossio.io.Forward-looking statements contained herein are based on estimates and assumptions of OSSIO management and are believed to be reasonable, though they are inherently uncertain and difficult to predict.MVM has invested in high growth healthcare businesses since 1997.